| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/JM00110A019 |
| P698 | PubMed publication ID | 2061926 |
| P50 | author | J. Martin Bollinger Jr. | Q88246612 |
| JoAnne Stubbe | Q55280 | ||
| P2093 | author name string | B Lippert | |
| M J Robins | |||
| C H Baker | |||
| V Samano | |||
| E Jarvi | |||
| J Banzon | |||
| R Resvick | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1879-1884 | |
| P577 | publication date | 1991-06-01 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase | |
| P478 | volume | 34 |
| Q39080441 | 5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors |
| Q68038574 | 8-Azidoadenosine and ribonucleotide reductase |
| Q32065795 | A novel approach towards studying non-genotoxic enediynes as potential anticancer therapeutics. |
| Q77947974 | Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682) |
| Q43620552 | Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). |
| Q33961375 | Clinical pharmacokinetics of 2'-deoxy-2'-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent |
| Q39380445 | Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy? |
| Q43593913 | Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines |
| Q40975420 | Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines |
| Q43844115 | Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer |
| Q40680519 | DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin |
| Q77749730 | Design and synthesis of a tetrahydropyran-based inhibitor of mammalian ribonucleotide reductase |
| Q30982752 | Design, synthesis, and anticancer activity of phosphonic acid diphosphate derivative of adenine-containing butenolide and its water-soluble derivatives of paclitaxel with high antitumor activity |
| Q46107625 | Dideoxy fluoro-ketopyranosyl nucleosides as potent antiviral agents: synthesis and biological evaluation of 2,3- and 3,4-dideoxy-3-fluoro-4- and -2-keto-beta-d-glucopyranosyl derivatives of N(4)-benzoyl cytosine |
| Q35124554 | Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine |
| Q35971682 | Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases. |
| Q27015719 | Exploiting the nucleotide substrate specificity of repair DNA polymerases to develop novel anticancer agents |
| Q41260361 | Gemcitabine and radiosensitization in human tumor cells |
| Q33761140 | Gemcitabine functions epigenetically by inhibiting repair mediated DNA demethylation |
| Q28543464 | Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer |
| Q34254837 | Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer |
| Q36831352 | Gemcitabine-mediated radiosensitization of human soft tissue sarcoma |
| Q35483623 | HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma |
| Q44956846 | Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway |
| Q36706248 | Improving nucleoside analogs via lipid conjugation: Is fatter any better? |
| Q40384053 | In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine |
| Q33791851 | Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: covalent modification |
| Q42142458 | Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines |
| Q42568349 | Insight into the mechanism of inactivation of ribonucleotide reductase by gemcitabine 5'-diphosphate in the presence or absence of reductant |
| Q36931187 | Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression |
| Q44865642 | Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study |
| Q34048376 | Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphate |
| Q37310211 | Nucleoside analogs: molecular mechanisms signaling cell death. |
| Q34288371 | Nucleoside analogues: mechanisms of drug resistance and reversal strategies. |
| Q35567292 | Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy |
| Q77749048 | Nucleosides and nucleotides. 176. 2'-Deoxy-2'-hydroxylaminocytidine: a new antitumor nucleoside that inhibits DNA synthesis although it has a ribonucleoside structure |
| Q77887925 | Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors |
| Q57176872 | Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer |
| Q38615375 | Positively charged cyclodextrins as effective molecular transporters of active phosphorylated forms of gemcitabine into cancer cells |
| Q48112706 | Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule. |
| Q73850903 | Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine) |
| Q41028153 | Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro |
| Q43152268 | Reactions of Trimethylsilyl Fluorosulfonyldifluoroacetate with Purine and Pyrimidine Nucleosides |
| Q40744000 | Reactions of purines-containing butenolides with L-cysteine or N-acetyl-L-cysteine as model biological nucleophiles: a potent mechanism-based inhibitor of ribonucleotide reductase caused apoptosis in breast carcinoma MCF7 cells |
| Q24794747 | Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene |
| Q37158252 | Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer |
| Q36919830 | Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells |
| Q33575608 | Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity |
| Q28619961 | Structure and function of the radical enzyme ribonucleotide reductase |
| Q48099410 | Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase |
| Q60919740 | Structure-guided design of anti-cancer ribonucleotide reductase inhibitors |
| Q77749744 | Synthesis and biological evaluation of a water soluble phosphate prodrug of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) |
| Q39042999 | Synthesis and cytostatic evaluation of 4-N-alkanoyl and 4-N-alkyl gemcitabine analogues |
| Q38879058 | The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX. |
| Q43619714 | The antitumor mechanism of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)-cytosine: effects of its triphosphate on mammalian DNA polymerases |
Search more.